These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27521112)

  • 1. Gastrointestinal potassium binding-more than just lowering serum [K(+)]: patiromer, potassium balance, and the renin angiotensin aldosterone axis.
    Emmett M; Mehta A
    Kidney Int; 2016 Sep; 90(3):484-6. PubMed ID: 27521112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Hyperkalemia: Stepping Into a New Frontier.
    Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
    J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia.
    Li L; Harrison SD; Cope MJ; Park C; Lee L; Salaymeh F; Madsen D; Benton WW; Berman L; Buysse J
    J Cardiovasc Pharmacol Ther; 2016 Sep; 21(5):456-65. PubMed ID: 26856345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
    Buysse JM; Huang IZ; Pitt B
    Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium: friend or foe?
    Rodan AR
    Pediatr Nephrol; 2017 Jul; 32(7):1109-1121. PubMed ID: 27194424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study.
    Riccio E; D'Ercole A; Sannino A; Hamzeh S; De Marco O; Capuano I; Buonanno P; Rizzo M; Pisani A
    J Nephrol; 2024 May; 37(4):1077-1084. PubMed ID: 38319545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer: A Review in Hyperkalaemia.
    Kim ES; Deeks ED
    Clin Drug Investig; 2016 Aug; 36(8):687-94. PubMed ID: 27380495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer: a significant advance in the management of hyperkalemia.
    Paton DM
    Drugs Today (Barc); 2015 Dec; 51(12):695-703. PubMed ID: 26798850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management.
    McCullough PA; Beaver TM; Bennett-Guerrero E; Emmett M; Fonarow GC; Goyal A; Herzog CA; Kosiborod M; Palmer BF
    Rev Cardiovasc Med; 2014; 15(1):11-23. PubMed ID: 24762462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
    Zannad F; Rossignol P; Stough WG; Epstein M; Alonso Garcia Mde L; Bakris GL; Butler J; Kosiborod M; Berman L; Mebazaa A; Rasmussen HS; Ruilope LM; Stockbridge N; Thompson A; Wittes J; Pitt B
    Int J Cardiol; 2016 Aug; 216():46-51. PubMed ID: 27140336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of plasma aldosterone by glucose-induced paradoxical hyperkalemia in the presence of suppressed renin-angiotensin system.
    Radó JP
    Endokrinologie; 1978 Apr; 72(1):51-6. PubMed ID: 688983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.